Every material Form 8-K Apimeds Pharmaceuticals US, Inc. has filed with the SEC since September 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Apimeds subsidiary MindWave Innovations signed a two-year Master Service Agreement with BlockAssure Inc. to build, deploy and operate AssureChain, a dedicated subnet of MindChain for recording BlockAssure's insurance and reinsurance processes on-chain. The filing does not disclose a dollar value for the fixed development fee, and operate and maintenance fees are still to be agreed, so the financial effect on shareholders cannot be measured from the filing.
Agreement took effect October 4, 2026; it renews automatically for one-year periods unless either party gives 90 days' notice.
Consideration includes a fixed development fee payable in quarterly installments, with no dollar amount stated in the filing.
MindWave is to receive an allocation of AssureCoin equal to 20% of its total supply, delivered when the token is created.
Development is planned over four quarters against agreed milestones, with BlockAssure acceptance-testing each module.
Apimeds Pharmaceuticals US, Inc. said interim Chief Financial Officer Erick Frim resigned effective immediately on September 29, 2026, with the company stating the resignation was not due to any disagreement on operations, policies or practices. The Board appointed Eric Sherb, a Certified Public Accountant, as Chief Financial Officer effective October 1, 2026, at a base salary of $60,000 per year. The change in the company's principal financial officer role is a leadership transition that shareholders may track.
Erick Frim resigned as interim CFO effective immediately; notice given September 29, 2026
Eric Sherb, age 40, appointed CFO by the Board on September 30, 2026, effective October 1, 2026
Sherb's base salary is $60,000 per year under an Executive Employment Agreement; equity awards may be granted in the future
Sherb's fractional CFO engagement at subsidiary MindWave Innovations Inc. will terminate in connection with his appointment
Apimeds Pharmaceuticals' subsidiary MindWave Innovations disclosed two 12-month technology agreements: one with AQUAE Holdings for the AQUAEChain platform (announced September 24, 2026) and one with Flash Sports & Media Holdings (FLZH) for the FlashChain network (announced September 29, 2026). Both agreements pay MindWave partly in tokens or shares, and the parties have not disclosed the aggregate dollar value, so the filing gives no figure for the effect on Apimeds' finances.
AQUAEChain agreement with AQUAE Holdings Pte. Ltd. was effective September 14, 2026; MindWave to receive a 20% allocation of ALCI Credits issued and outstanding, calculated quarterly.
FlashChain agreement with Flash Sports & Media Holdings, Inc. (FLZH) runs 12 months; MindWave to receive FLZH common shares and a 20% allocation of FLASH TOKEN total supply.
Parties have not publicly disclosed the aggregate dollar value of the consideration for the FlashChain agreement.
FlashChain agreement provides for an annual maintenance fee equal to 50% of the applicable contract consideration, as specified in the agreement.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Apimeds Pharmaceuticals US, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →